Sandhill Capital Partners LLC Reduces Stake in Illumina, Inc. (NASDAQ:ILMN)

Sandhill Capital Partners LLC decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 6.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 262,927 shares of the life sciences company's stock after selling 18,592 shares during the quarter. Illumina comprises approximately 2.8% of Sandhill Capital Partners LLC's investment portfolio, making the stock its 19th largest position. Sandhill Capital Partners LLC owned approximately 0.17% of Illumina worth $35,135,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of Stockton raised its stake in Illumina by 3.8% during the fourth quarter. Bank of Stockton now owns 2,162 shares of the life sciences company's stock worth $289,000 after buying an additional 80 shares during the last quarter. Stephens Inc. AR raised its position in shares of Illumina by 1.4% in the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company's stock worth $885,000 after acquiring an additional 90 shares in the last quarter. Spire Wealth Management lifted its stake in shares of Illumina by 26.0% in the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company's stock valued at $63,000 after purchasing an additional 97 shares during the period. IFP Advisors Inc boosted its position in shares of Illumina by 19.1% during the 4th quarter. IFP Advisors Inc now owns 617 shares of the life sciences company's stock valued at $82,000 after purchasing an additional 99 shares in the last quarter. Finally, Brooklyn Investment Group grew its stake in Illumina by 20.5% during the fourth quarter. Brooklyn Investment Group now owns 611 shares of the life sciences company's stock worth $82,000 after purchasing an additional 104 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several brokerages have issued reports on ILMN. Piper Sandler boosted their price target on Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Canaccord Genuity Group dropped their target price on shares of Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a research report on Tuesday, March 11th. Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. TD Cowen downgraded shares of Illumina from a "buy" rating to a "hold" rating and decreased their price target for the company from $177.00 to $140.00 in a research note on Friday, February 7th. Finally, Robert W. Baird cut their price objective on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $138.70.

Illumina Stock Up 4.9 %

Shares of ILMN stock traded up $3.52 on Friday, hitting $74.78. The stock had a trading volume of 3,040,860 shares, compared to its average volume of 2,268,017. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The business has a 50 day moving average of $88.58 and a 200 day moving average of $122.25. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The stock has a market cap of $11.85 billion, a price-to-earnings ratio of -9.74, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.